Global Hyperparathyroidism Treatment Market - 2023-2030

Overview

Hyperparathyroidism occurs when individual parathyroid glands create high amounts of parathyroid hormone in the bloodstream. These glands, located behind the thyroid at the bottom of your neck, are about the size of a grain of rice. There are two types of hyperparathyroidism. In primary hyperparathyroidism, an enlargement of one or more of the parathyroid glands causes the overproduction of parathyroid hormone. This causes high calcium levels in the blood, which can cause a variety of health problems. Surgery is the most common treatment for primary hyperparathyroidism.

Secondary hyperparathyroidism occurs due to another disease that first causes low calcium levels in the body. Over time, increased parathyroid hormone levels occur as the body fights to keep the calcium level up in the standard range. This is common in kidney disease and after certain intestinal surgeries or diseases.

Symptoms of parathyroid dysfunction can be mild or severe, ranging from osteoporosis to kidney stones, excessive urination, abdominal pain, weakness, depression, bone and joint pain, frequent illness complaints, nausea, vomiting, or loss of appetite.

Furthermore, the global hyperparathyroidism market is driven by various factors like growing awareness and diagnosis, research and development, advancements in medical technology and others that will drive this market to grow during the forecast period.

Dynamics

Rise in The Prevalence of Parathyroid Cancers

The rise in the prevalence of parathyroid cancers is one of the significant key factors that drive the market to grow during the forecast period. Nearly all tumours that develop in the parathyroid gland are benign. It is important to note that even benign parathyroid tumours need prompt medical care. If they are not removed completely or properly, they can come back and be very difficult to control. This type of tumour may result in hypercalcemia of the blood that is difficult to control or could cause death.

For instance, according to the American Society of Clinical Oncology (ASCO), Parathyroid cancer is quite rare. There are likely fewer than 100 cases diagnosed each year in the United States. The disease is most often diagnosed in people older than 30. Men and women are equally affected. Women have a slightly better prognosis, which is the chance of recovery.

Rise in The Geriatric Population

Hyperparathyroidism is more frequent in elderly people, and as the world population ages, the condition's incidence is projected to grow, increasing the need for therapies. For instance, according to the article published in the National Library of Medicine 2022, the Prevalence of Primary Hyperparathyroidism (PHPT) in the geriatric population is a common disease that increases in prevalence with advancing age. Prevalence peaks in women around 70-79 years of age (492 per 100,000) and in men over 80 years old (264 per 100,000).

Rise in the Technological Advancements

Several market players are coming with new technology advancements for the treatment of hypoparathyroidism. Surgery remains the definitive treatment for PHPT, and advances in screening, evolving indications for surgery, new imaging modalities, and improvements in intra-operative methods have greatly changed the landscape. Surgery continues to produce excellent results in the hands of an experienced parathyroid surgeon. Also, there have been advancements in Newer imaging techniques and surgical adjuncts that continue to advance the cure of diseases.

Product Recalls

Product recalls and some side effects associated with the treatment are some of the restraints that hamper the market growth during the forecast period, the common complications include breast pain and tenderness, dizziness, headaches and others. For instance, in September 2019, Takeda Pharmaceutical Company Limited issued the U.S. recall of NATPARA. The recall is because of a potential issue associated with rubber particulates rising from the rubber septum of the NATPARA cartridge.

Also, Genetic tests in homecare settings, despite their benefits, hinder market growth due to concerns about privacy and control over patient genetic information. This is particularly important for secondary hyperparathyroidism treatment, as customers forfeit control over their genetic material and related data.

Segment Analysis

The global hyperparathyroidism treatment market is segmented based on type, drug type, route of administration, distribution channel and region.

The Secondary Hyperparathyroidism Segment From The Type Segment Accounted For Approximately 42.5 % of The Hyperparathyroidism Share

The secondary hyperparathyroidism segment from the type segment accounted for 42.5% and it is expected to be dominated during the forecast period. Secondary hyperparathyroidism occurs when the parathyroid glands become enlarged and release too much PTH, causing a high blood level of PTH.

For instance, Pathalys Pharma, Inc., a private, late-stage biopharma company co-founded by Catalyst Pacific and DaVita Venture Group, and Launch Therapeutics, a clinical development company, announced a collaboration to advance phase 3 clinical trials for upacicalcet for the treatment of secondary hyperparathyroidism (SHPT) in patients on hemodialysis. Launch Tx is backed by funds managed by global investment firm Carlyle and its life sciences franchise Abingworth.

Geographical Penetration

North America Accounted for Approximately 38.4% of the Market Share

North America is estimated to hold about 38.4 % of the total market share throughout the forecast period, due to ongoing clinical trials, increasing thyroid-related diseases and increasing initiatives taken by pharmaceutical organizations to generate novel formulations.

For instance, according to the Clinical trial.gov reports an ongoing study titled 18F-Fluorocholine Positron Emission Tomography (PET) for Detecting Parathyroid Adenomas. The study aims to investigate the accuracy of PET in detecting hyperfunctioning parathyroid glands in surgical patients with primary hyperparathyroidism. The studies currently taking place at the University of California, San Francisco which is enrolled with 140 participants, currently where the study is expected to complete by June 2027.

Competitive Landscape

The major global players in the market include: OPKO Health, Pfizer, Amgen, Abbvie, Dr Reddy's, Sanofi, Teva Pharmaceuticals, Merck KGaA, ONO Pharmaceuticals, Xediton Pharmaceuticals and among others.

COVID-19 Impact Analysis

COVID-19 had a substantial impact on the global hyperparathyroidism treatment market where, according to clinical trials.gov trials were getting conducted and where researchers evaluated the results of serum parathyroid hormone, calcium, phosphorus, and alkaline phosphatase tests in patients who were symptomatic and hospitalized with COVID-19 infection.

Participants also evaluated the relationship of parathormone with white blood cells, neutrophil/lymphocyte ratio, C reactive protein, fibrinogen, procalcitonin, ferritin, and D-dimer in these patients. The researchers compared the parathyroid hormone levels of patients with COVID-19 infection with the parathyroid hormone levels of healthy individuals without COVID-19 infection and parathyroid disease.

By Type

• Secondary Hyperparathyroidism
• Primary Hyperparathyroidism

By Drug Type

• Calcimimetics
• Hormone replacement therapy
• Bisphosphonates
• Others

• Route of Administration
  • Oral
  • Parenteral

By Distribution Channel

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• In May 2023, Amolyt Pharma disclosed an oral presentation at the 25th European Congress of Endocrinology (ECE) 2023. The presentation emphasizes the potential benefits of eneboparatide as a therapy for hypoparathyroidism, a condition in which numerous people have or are susceptible to acquiring osteopenia and osteoporosis.
• On August 2022, Ascendis Pharma A/S announced that it has submitted a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for Trans Con PTH, an investigational prodrug designed to restore parathyroid hormone to physiological levels over 24 hours in adult patients with hypoparathyroidism. Trans Con PTH has been granted Orphan designation in the United States and European Union.

Why Purchase the Report?

• To visualize the global hyperparathyroidism treatment market segmentation based on type, drug type, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of hyperparathyroidism treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global hyperparathyroidism treatment market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies